Business Wire

CA-NEXON-AMERICA

Share
Embark on the First of Two Fantasy Life Updates in Mabinogi’s Winter Season

Mabinogi, Nexon’s free-to-play fantasy MMORPG, begins the winter season with two meaningful events. Entitled “NEXT,” these two-part game updates include overhauled character growth, faster and more convenient leveling, plus revised tutorials and UI improvements during November, and the introduction of Arcana talents in December!

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117006144/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mabinogi, Nexon America's fantasy life MMORPG (Graphic: Business Wire)

Blaanid, the eager Memory Spirit, has prepared a new tutorial for all Milletians, making leveling and questing in Mabinogi faster overall! And Memoir Quests have been changed to now reward you for completing Generation quests. In Mabinogi's Masterpiece Update, Original Generation 1-3 Questline has been revamped to provide a friendly experience for new players as well as the ability to replay the quests for existing players. Mabinogi players new and old will find the starting experience even more user friendly! These updates, along with other elements such as Dan Advancement test improvements, and balance changes to Renown, Grandmaster, and Crusader skills are designed to drastically improve the early to mid-game leveling experience for all Milletians.

Memoir Rewards

  • Comfortable Growth - The perfect path to growth is Blaanid’s Brave Boost, which will grant you:
    • Skills trained by Talent
    • Upgraded and Reforged Memorial weapons
    • Pet & Doll Bag Support
    • and more!
  • Essential Skills & Benefits - Blaanid prepared even more gifts for new Milletians!
    • Your stats are increased as each Memoir Book is completed.
      • Recall Book Stage 1~4
      • Movement Speed +2%~8%
      • All Stats +1~4
      • Additional +1~4 AP at Rebirth!

Memorial Link

  • You can obtain this skill by completing the 2nd Memoir Book in Blaanid’s Brave Boost quests!
    • Skill allows a soul connection with pets
    • Pets can be used to draw enemy aggro
    • As pets increase in level and skill, pets and player Defense and Protection stats increase proportionally

In addition to the above improvements, Quests have been reorganized, only displaying essential quests now, and skill training has also been improved - less training points are required and more EXP is earned to quickly achieve high ranked skills. Lastly, Mabinogi has removed CP Training, meaning monster levels are no longer relevant for your training requirements. Other changes, such as teleporting to Moon Gate and Mana Tunnels, were improved in this update to make it more convenient for new and returning players to traverse the world map.

In part two of the “NEXT” update coming in December, Mabinogi unveils a new pair of Hybrid Talents, merging two talent styles into a single devastating package! Get ready to experience the almighty power of the Elemental Knight or the soulful skill of the Harmonic Saint when the Arcana update arrives later in December!

These reasons, and many more, are why your “NEXT” MMORPG should be Mabinogi!

For more information on Mabinogi, visit the official website and follow @MabiOfficial on Twitter for the latest updates.

Assets: Image

Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord

About Mabinogi http://mabinogi.nexon.net/

Released in 2008, Mabinogi is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.

About Nexon America Inc. https://www.nexon.com/

Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117006144/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye